а

A-MAb case study 552, 553, 556, 564, 579 AAC see Anything And Chromatography ABRF see Association of Biomolecular **Research Facilities** accelerated stability testing 189 acetyl-CoA synthase (ACS) 515, 516 AcMNPV see Autographa californica multinucleopolyhedrovirus ACS see acetyl-CoA synthase active pharmaceutical ingredients (API) 587, 601, 602, 803, 839 acyl transfer reactions 208, 209 ADA see antidrug antibodies ADCC see antibody-dependent cellular cytotoxicity adenine diphosphate/triphosphate (ADP/ATP) 536, 537, 621-623, 625 adeno-based vaccines 845-849 adenylyltransferase 536, 537 adherent HEK-293 cells 821, 822, 831 ADP/ATP see adenine diphosphate/ triphosphate adventitious agent tests 597 AF4 see asymmetric flow field-flow fractionation affinity chromatography 225-282 - alternative ligands 229, 250, 251 - avidin and streptavidin 248, 249 - bacterial proteins 227, 228, 242-246 - benzhydroxamic acid 256, 257 - biological ligands 226-228, 239-251 - biomimetic ligands 251, 258-269 - biopharmaceutical applications 269-271 - boronate 228, 256 - chromatographic theory 230–232 - continuous countercurrent chromatography 776, 777, 781 - de novo affinity ligands 260-269

- dye-based ligands 228, 257, 258 - future perspectives 271, 272 - glutathione 248 – heparin 247, 248 - histidine 254, 255 - history and context 225, 226 - hydrophobic ligands 228, 253 - immobilized metals 228, 252, 253 - immunoaffinity adsorbents 239-242 - lectins 227, 246, 247 - matrix selection and ligand immobilization 232-237 - mixed-mode 229, 255, 256 - monoclonal antibodies 127-129 - nucleic acids 227, 228, 249, 250 - process design and management 667, 682 - protein purification 108 - purification pyramid 238 role in the separation sciences 229, 230 - single-use technologies 798 - synthetic and designed ligands 228, 229, 240. 251-269 - theory and methods overview 230-239 - thiophilic ligands 228, 253, 254 - virus-like particles 152 - vitamins and hormones 227, 249 - see also hydroxyapatite chromatography affinity precipitation 229, 272 agarose-based matrices 233, 234, 236 aggregation – continuous countercurrent chromatography 787 - efficiency of bioprocesses 632-638 - hydroxyapatite chromatography 284, 285, 317, 319, 320

- membrane chromatography 404-406
- monoliths 342

Biopharmaceutical Production Technology, First Edition. Edited by Ganapathy Subramanian. © 2012 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2012 by Wiley-VCH Verlag GmbH & Co. KGaA.

- therapeutic proteins 165, 166, 173, 174, 180, 182, 183, 186, 192, 193 - virus-like particles 149, 150, 153, 154 air–liquid interfaces 170, 171 albumin 341 alkaline lysis 19, 20 Alzheimer's disease 499, 508 amine conjugation 204–206 amino acids - affinity chromatography 235-237 - efficiency of bioprocesses 643, 644 - fed-batch processes 518-520, 535, 536 - plasmid DNA 9, 19 - proteomics 485, 493-495, 500, 501 - therapeutic proteins 177 ammonia production 626, 629-631 amplification systems 8, 9, 18, 19 analytical ultracentrifugation (AUC) 155, 193 animal-derived products 587, 589, 592-596 anion-exchange chromatography see ion-exchange chromatography antibiotics 696–699 antibodies - affinity chromatography 227, 242, 245-247, 259-262, 265, 268 - biosensors 463, 465-467 - hydroxyapatite chromatography 297-300, 313-321 - membrane chromatography 390, 391, 403-406 - monoliths 340-342 - single-use technologies 820, 821 - see also monoclonal antibodies antibody-dependent cellular cytotoxicity (ADCC) 546, 575, 576 antidrug antibodies (ADA) 165, 173 antigens affinity chromatography 249 – plasmid DNA 6, 7 antisense RNAS 8, 9, 11 antitrypsin ligands 264 Anything And Chromatography (AAC) concept 679-685 AOX genes 55 API see active pharmaceutical ingredients apparent cell growth 626 aqueous two-phase systems (ATPS) 22, 23 Arthrobacter spp. 98 aseptic connections 801, 806, 824-833 aseptic transfer systems 797, 798 asparagine deamidation 171, 172 aspartate isomerization 171, 172 Aspergillus japonicus 361, 362

A. niger 360 Association of Biomolecular Research Facilities (ABRF) 479, 480 asymmetric flow field-flow fractionation (AF4) 193 ATPS see aqueous two-phase systems AUC see analytical ultracentrifugation autoclaving 798, 800, 801, 824, 831 Autographa californica multinucleopolyhedrovirus (AcMNPV) 55, 56, 144 autolysis 19.20 automation systems 806-809 auto-oxidation reactions 172, 173 auxotrophic markers 10-12 avidin 248, 249

b

 β -methylnorleucine (β -MNL) 518 B19 virus 608 baby hamster kidney (BHK-21) 52 Bacillus cereus 83, 84 B. subtilis - cell disruption processes 88, 89 - fed-batch processes 514-517, 522 - hydroxyapatite chromatography 323 protein production technologies 49, 50 bacteria - affinity chromatography 227, 228, 242-246, 268 - cell disruption processes 82–84, 88, 89, 91, 95, 98, 99, 102, 103 - fed-batch processes 514-518, 520, 522, 531-537 - hydroxyapatite chromatography 322, 323 - membrane chromatography 377-379 - PEGylated proteins 205 - plasmid DNA 3, 4 - process design and management 666 - protein production technologies 43, 44, 47-50, 63, 65, 66 - single-use technologies 812-814 - virus-like particles 139-141, 143, 146, 147 bacteriophages 352, 353, 358 baculovirus 346, 353 baculovirus-insect cell expression 43, 55-57, 144, 145 bags 755-757, 794-798, 809, 823, 824, 829 barrier properties 756, 757 baseline risk 590-599 batch processes - cell disruption processes 96 - continuous chromatography 113, 114, 121-124, 126, 127, 130, 135

 – continuous countercurrent chromatography 783, 789 - efficiency of bioprocesses 625, 626 - process design and management 672-679, 726, 727 - protein production technologies 63, 64 - see also fed-batch processes batch-to-batch variability 235, 236 BDNF see brain-derived neurotrophic factor bead milling 81, 95-98, 103 Beadle and Tatum's one gene/one enzyme concept 490, 496, 497 benzhydroxamic acid 256, 257 1,6-benzyl elimination reactions 209, 210 BHK-21 see baby hamster kidney Biacore biosensors 453, 457, 460-465 big 1-string facilities 669, 670 bind-and-elute mode 377, 379, 381, 390, 391 bioconversion of target molecules 360-362 bioinformatics 506 bio-layer interferometry (BLI) 453, 456-465, 467-470 biological ligands - affinity chromatography 226-228, 239-251 - avidin and streptavidin 248, 249 - bacterial proteins 227, 228, 242-246 - glutathione 248 – heparin 247, 248 - immunoaffinity adsorbents 239-242 - lectins 227, 246, 247 - nucleic acids 227, 228, 249, 250 - vitamins and hormones 227, 249 biological state variables 641, 642 biomarkers 479, 503-505, 507 biomimetic ligands 251, 258-269 biomineralization 295, 296 bioreactors - plastics 748, 757-763 - single-use technologies 821, 824-835, 848-850, 854-856 biosafety levels 848 biosensors 447-471 - bio-layer interferometry 453, 456-465, 467-470 - biopharmaceutical production and processing 464-469 characterization of biopharmaceuticals 466-468 - commercial applications 448-464 - comparison of biosensor chips 458-464 - context 447, 448 - current technologies 451-453

- principles 448, 449 - purification on chromatography columns 465, 466 - quantification of therapeutics and minor impurities 464, 465 - resonant waveguide grating 452-455, 458-464 - sample handling 455-458 - surface plasmon resonance 452-458, 460-465, 467-470 - throughput comparison 462-464 - vaccine design and efficacy 468, 469 bioseparations 112, 113 BioSMB[™] technology 780, 781, 786–789 biotin-streptavidin 248, 249, 383 BL21 strain (E. coli) 48 BLI see bio-laver interferometry Bodenstein numbers 527-529 boronate affinity chromatography 228, 256 bovine serum albumin (BSA) - affinity chromatography 226 - membrane chromatography 387 - PEGylated proteins 199, 204, 215 bovine viruses 593-596 brain-derived neurotrophic factor (BDNF) 507 breakthrough curves 384-386, 415, 421, 422 Brevundimonas diminuta 812 brute-force optimization 726, 727 BSA see bovine serum albumin bubble plots 725, 735, 736

- kinetic analysis 466-468

464-467

- monoliths 360

- labeled versus label-free 449-455,

С

Cache valley virus (CVV) 599 camelid antibodies 241, 242 cAMP see cyclic adenosine monophosphate Campylobacter jejuni 47 capacity planning 719, 731-735 capillary zone electrophoresis (CZE) 191, 192 capsomeres 141, 142, 152–154 capsule filter devices 800, 801, 824-833 capture agents 459 capture, intermediate purification, and polishing (CIPP) - affinity chromatography 230 – continuous countercurrent chromatography 772, 778, 781, 785, 786

- hydroxyapatite chromatography 302, 303 - process design and management 665 capture and polish from supernatant 127-129, 131 carbohydrate oxidation 208 carbon catabolite proteins (Ccp) 517 carbon microspheres 333 carrousel chromatography systems 773, 774, 786, 787 casein 59 CAT see chloramphenicol acetyl transferase cation-exchange chromatography see ion-exchange chromatography CBA see Critical Business Attributes Ccp see carbon catabolite proteins CD see circular dichroism CDC activity 562, 563, 566-568, 575, 576 CDMO see contract development and manufacturing organizations CDS see centrifugal disk sedimentation CECF see continuous exchange cell-free reactor cell banks 6, 586, 587, 835, 837 cell-based bioassays 190, 191 cell-cell adhesion 632-638 cell compression 86-89 cell culture - microenvironments 617, 618, 650 – plastics 747, 748 - single-use technologies 821, 824-827 see also bioreactors cell disruption processes 81-105 - bead milling 81, 95-98, 103 - cell mechanical strength 85-89 - cell structure and disruption strategies 83-85 - cellular debris 100-103 - chemical/enzymatic techniques 82-84, 98-100.103 - context 81-83 - high-pressure homogenization 81, 89-95, 102.103 - mechanical techniques 81-98, 102, 103 - mechanisms 90, 91 - modeling 88, 91-98, 102, 103 cell-free assembly 140-142, 147, 157, 158 cell-free protein production 44, 62-65 cell lysis – efficiency of bioprocesses 634 - plasmid DNA 6, 19, 20 protein production technologies 64 cellular debris 100-103 cellulose 748, 751

cellulose-based matrices - affinity chromatography 233, 234, 236 - membrane chromatography 380-382 centrifugal disk sedimentation (CDS) 101, 102 centromeric plasmid (YCP) vectors 54, 55 ceramic hydroxyapatite spheres 286-289, 314-319 cerebrospinal fluid 499 cetuximab 126 CFCF see continuous mode cell-free reactor CFD see computational fluid dynamics chaotropes 168, 169 charge variant separation 125-127 chelating agents - affinity chromatography 252, 253 - hydroxyapatite chromatography 285, 287, 288, 296, 297, 311, 312, 319 therapeutic proteins 178 chemical cell disruption processes 82-84, 98-100.103 Chinese hamster ovary (CHO) cell lines - continuous countercurrent chromatography 776 - efficiency of bioprocesses 627-631, 632-638 - glycosylation 549 - monoliths 341, 358 - plastics 759, 761-763 - process design and management 659, 660 - risk management 601, 603, 604 - virus-like particles 145, 146 chloramphenicol acetyl transferase (CAT) 65 CHO see Chinese hamster ovary chromatographic techniques - biosensors 465, 466 - chromatographic theory 230-232 - decision tree 135, 136 - PEGylated proteins 203, 204, 210-216 - plasmid DNA 23-26 - plastics 760, 761, 764, 765 - process design and management 664, 665, 667, 677-689, 692-694, 725-728, 735, 736 - protein production technologies 59 - purification pyramid 238 - single-use technologies 798, 799, 804, 834, 839-844 - therapeutic proteins 191-193 - virus-like particles 150-152 - see also individual techniques and materials

chromosomal DNA 17-21, 302, 322, 323

CI see confidence intervals CIM see convective interaction media CIP see cleaning-in-place CIPP see capture, intermediate purification, and polishing circular dichroism (CD) 187, 194 CLC see conjoint liquid chromatography cleaning-in-place (CIP) - affinity chromatography 233, 243, 251, 259.263 - continuous chromatography 112, 116-119, 128, 129 - process design and management 667-678, 680 - single-use technologies 821, 834, 842 - virus-like particles 151, 152 clearance of animal-derived materials 600, 601 click chemistry 209 clinical trials 605, 606, 728-730 closed loop bioprocess control 614, 615, 648, 649, 651, 652 CMO see contract manufacturing organizations CMV see cytomegalovirus codon use 7 COG see cost of goods Committee for Proprietary Medicinal Products (CPMP) 602-606 comparability 545-583 component transfer 797, 798 computational fluid dynamics (CFD) – cell disruption processes 93–95 - fed-batch processes 514, 515, 521 concanavalin A 246, 247 confidence intervals (CI) 427-430, 432, 433 conjoint liquid chromatography (CLC) 340, 341 connectors 801, 806, 822-829 consensus immunogens 7 containers and closures 179 contamination events 585, 586, 589 continuous chromatography - applications 111, 112, 120-133 - basic principles 108, 109 - batch chromatography 113, 114, 121-124, 126, 127, 130, 135 - biopharmaceutical market overview 107, 108 - bioseparations 112, 113 - context 107 - decision tree 135, 136 - enabling features and economic impact 106, 134, 135

- four-column MCSGP with separate CIP position 116-118 - four-column MCSGP with separate continuous feed position 118, 119 - generic purification problem 114 - limitations of SMB 112 - monoclonal antibodies 107, 111, 125-129 multicolumn countercurrent solvent gradient purification 107, 109, 112-135 - polypeptide purification 120-125 - principles of MCSGP 113-120 - protein purification 107-137 - purification overview 108 - separations with more than three fractions 119.120 - simulated moving bed process 109-113 - six-column MCSGP principle 114 - size-exclusion chromatography 129-133 - three-column MCSGP principle 114, 115 continuous countercurrent chromatography 769-791 - affinity chromatography 776, 777, 781 - aggregation 787 - biopharmaceutical industries 776-781 – BioSMB[™] technology 780, 781, 786–789 - capture chromatography 772, 778, 781, 785.786 - case studies 786-789 - evolution of process technology 769-773 - fractionation chromatography 774, 775, 783, 784 - hydrophobic interaction chromatography 781, 787 - industrial applications 774-776 - industry drivers 776-778 - ion-exchange chromatography 769-773, 775, 776, 781 - key challenges 779, 780 - mass transfer kinetics 782, 783 - multicolumn systems 772-774, 779-781, 786, 787, 789 - performance prediction 783 - polishing processes 778 - prepacked columns 780, 781 - process design and management 779-786 - protein A chromatography 786, 787 - simulated moving bed process 770-775, 778-781, 784, 786-789 - single-use technologies 777, 778, 780, 786, 789

size-exclusion chromatography 782, 784, 788, 789

- systems 773, 774, 779-781, 786, 787 - thermodynamic equilibrium 781, 782 continuous exchange cell-free reactor (CECF) 64, 65 continuous mode cell-free reactor (CFCF) 64.65 continuous mode facilities 669, 672-679 continuous stirred tank reactors (CSTR) 97 continuous urea-formaldehyde resins 333 contract development and manufacturing organizations (CDMO) 745-747 contract manufacturing organizations (CMO) – continuous countercurrent chromatography 775, 777 - process design and management 725, 731, 734, 735 Control Space (CS) 551, 558-561, 579 control systems 808 convective interaction media (CIM) - monoliths 340-343, 348-353, 355, 356, 360-363 - virus-like particles 150, 151 copy numbers plasmid DNA 8, 11 protein production technologies 61 cost analysis - continuous countercurrent chromatography 787 - membrane chromatography 391-393 - optimization and comparability 545-547, 576 - process design and management 660-662, 664, 666-678, 686-689, 692-699 – proteomics 477, 478 - single-use technologies 800, 801, 819, 838, 841, 843, 848-851, 856, 857 cost of goods (COG) - continuous chromatography 106, 135 - process design and management 660, 661, 667, 671, 679, 694, 717, 722-725, 728, 729, 735, 736 Coulter counting see electrical sensing zone covalent affinity chromatography 229 CPMP see Committee for Proprietary Medicinal Products CPP see Critical Process Parameter CQA see Critical Quality Attribute Critical Business Attributes (CBA) 646 Critical Process Parameters (CPP) - efficiency of bioprocesses 626, 639, 646 - glycosylation 551

Critical Quality Attributes (CQA) - efficiency of bioprocesses 615, 616, 626, 646 - glycosylation 551-553, 556, 557, 563-571 - integrated process design 707-709 cross-competition analysis 463 cross-contamination - biosensors 456, 469 membrane chromatography 389, 392 - plastics 745, 746 - process design and management 679 cross-flow ultrafiltration 798, 800, 804 cross-interactions 433, 434, 437 cross-linking 234, 235-237, 380, 381 cryogels 334 cryogenics 755 crystallization processes 684, 685 CS see Control Space CSA see cumulative sedimentation analysis CSTR see continuous stirred tank reactors cultivation devices 757-763 cultivation media 6. 16-19 cumulative sedimentation analysis (CSA) 102 CVV see Cache valley virus cyclic adenosine monophosphate (cAMP) 516 cysteine conjugation 206, 207 cytochrome *c* 390, 391 cytomegalovirus (CMV) promoters 10 cytoplasmic inclusion bodies 99, 100 CZE see capillary zone electrophoresis

d

Damkoehler numbers 527-530 DAPI see 4',6-diamidino-2-phenylindole Darwin's theory of evolution 490 data acquisition 808 data visualization 721, 722 DCS see distributed control systems de novo affinity ligands 260-269 decision-support tools 719-723, 739 Define-Measure-Analyze-Design-Verify (DMADV) 428, 429 Define-Measure-Analyze-Improve-Control (DMAIC) method 428 density gradient methods - membrane chromatography 395-397 - ultracentrifugation 351 deoR genes 14 deoxyribonucleic acid see DNA Design of Experiments (DoE) 411, 428, 440 - glycosylation 551-553, 579 - process design and management 690, 691 Design Space (DS) - glycosylation 547, 551-580 - integrated process design 707-715 - risk management 585 deterministic analysis 721, 722 development costs 392 DH5α strain (E. coli) 14–16 DHFR see dihydrofolate reductase diafiltration 798, 800, 804 4',6-diamidino-2-phenylindole (DAPI) staining 632, 633, 636 differential gel electrophoresis (DiGE) 482 differential scanning calorimetry (DSC) - biosensors 450 - therapeutic proteins 166, 167, 177, 185-187 differential scanning fluorimetry 187 differentiation of multicellular organisms 501, 502 DiGE see differential gel electrophoresis dihydrofolate reductase (DHFR) 50 Dip and Read format 455, 457, 459-461, 470 diseasome concept 503, 504 displacement chromatography 309-313 disposables see single-use technologies dissolved oxygen (DO) - efficiency of bioprocesses 627 - scale-up 514, 522-525, 529-532 distributed control systems (DCS) 806 disulfide bridges - affinity chromatography 236, 237 - PEGylated proteins 206, 207 DLS see dynamic light scattering DMADV see Define-Measure-Analyze-Design-Verify DMAIC see Define-Measure-Analyze-Improve-Control DNA aptamers 227, 228, 249, 250 DNA delivery 817 DNA removal - membrane chromatography 398, 404 - monoliths 357, 358, 361 - process design and management 659 single-use technologies 798 DNA sequencing 491-493, 632, 633, 641 DNA structure 490, 491 DNA vaccines 3-41 DO see dissolved oxygen DoE see Design of Experiment domain ontology model (DOM) 557, 577, 578

drug development 507 drug discovery 506, 507 drying 170 DS see Design Space DSC see differential scanning calorimetry dye-based affinity ligands 228, 257, 258 dynamic binding capacity - biosensors 466 - membrane chromatography 384-386 - monoliths 335, 351, 352, 354-358 - Quality by Design 415, 422 dynamic light scattering (DLS) 101, 154, 155 dynamic object-oriented quality concept 614, 615 e EBC see expanded-bed chromatography economic factors - continuous chromatography 106, 134, 135 – continuous countercurrent chromatography 787 - optimization and comparability 545-547, 576 - plastics 746 - process design and management 660-662, 664, 666-678, 686-689, 692-699, 717, 722-725, 728-739 - proteomics 477, 478 - Quality by Design 428, 429 - single-use technologies 800, 801, 821, 838, 842, 843, 848-854, 856, 857 economical modeling 391-393 ECP see elution at characteristic point Edman degradation 497, 498 EDTA see ethylenediamine tetraacetic acid efficiency of bioprocesses 613-656 - biological demands 617-626 - byproducts of metabolism 624, 626, 629-631 - cell culture microenvironments 617. 618 - cell-cell adhesion and aggregation 632-638 - context 613, 614 - data analysis 644-645 - engineering meets biology 616, 617 - extended growth model 635-638 - glycosylation 626-632

- knowledge-based process understanding 646
- nutrient metabolism 618-626

- PAT and QbD compliant bioprocesses 613-616, 626, 638-653 - primary data acquisition 640-644 process understanding and control 639-649 - proof-of-concept 647, 648 speed and quality in bioprocess development 649-652 technical and engineering solutions 638-652 electrical sensing zone 101 electron microscopy 101, 598 electrospray differential mobility analysis (ES-DMA) 156, 157 electrospray ionization (EPI) 500 ELISA see enzyme-linked immunosorbent assays elution at characteristic point (ECP) method 415.416 elution chromatography 305-309 end of production (EOP) cells 602-604 end-product filling 802 endA mutations 12, 15-17 endogenous retroviruses 597-599 endotoxins see lipopolysaccharide enhanced QbD 554-580 enterprise resource planning (ERP) 806 enveloped viruses 600, 601, 605 environmental factors 753-755 enzymatic cell disruption processes 82-84, 98-100 enzyme inhibition 363, 364 enzyme-intrinsic properties 362-364 enzyme-linked immunosorbent assays (ELISA) - biosensors 449, 464, 466, 467, 469 - monoliths 339 enzyme reactors 358-364 enzymes 227 EOP see end of production EPI see electrospray ionization Epic biosensors 458-464 epidemiology 592-596 epigenomics 489 episomal plasmid (YEP) vectors 54, 55 EPO see erythropoietin epoxy membranes 383 equipment qualification 809-811 ERP see enterprise resource planning erythropoietin (EPO) – glycosylation 567 - therapeutic proteins 165, 167, 168, 173, 188, 190, 191

ES-DMA see electrospray differential mobility analysis Escherichia coli - affinity chromatography 252, 253, 268 - cell disruption processes 82–84, 91, 95, 99, 102, 103 - fed-batch processes 515-518, 520, 522, 531-537 – hydroxyapatite chromatography 322 - monoliths 340, 352 - PEGylated proteins 205 - plasmid DNA 3-41 - process design and management 666, 695, 696 - protein production technologies 43, 44, 47-50, 63, 65, 66 - virus-like particles 139, 140, 143, 146, 147.152 ethylene vinyl acetate (EVA) 748, 749, 751, 756 ethylene vinyl alcohol (EVOH) 756 ethylenediamine tetraacetic acid (EDTA) 178, 296, 312, 319 EVA see ethylene vinyl acetate EVOH see ethylene vinyl alcohol evolution by natural selection 490 excipients see formulation processes expanded-bed chromatography (EBC) 679-681 experimental model parameter determination 414-425 - fluid dynamics 416-418 - isocratic pulses 415, 416, 419, 420 - isotherm parameters 414, 416, 419, 426, 427 - mass transfer kinetics 417-425 - robustness analysis 426-431, 437-439 extended growth model 634-638 extractables 753-755 extraction processes 6, 19, 20

f

facility design
robustness and uncertainty 719, 725–737
single-use technologies 842–849
facility-fit issues 737
Factory Acceptance Test (FAT) 809, 834
failure mode and effects analysis (FMEA) 552, 553, 563, 564
FAT see Factory Acceptance Test
fat globule dispersion 90

fed-batch processes - amino acid synthesis 518-520 - E. coli cultivations in two-compartment reactors 531-537 - future perspectives 537, 538 - hydrodynamic conditions 526-529 - main carbon metabolism 515-518 - oxygen transfer processes 529-531 - performance characteristics 532-535 - plasmid DNA 17-19 - process design and management 723, 725 - protein production technologies 52, 53 - quality control 513-538 - scale-down reactors 520-523 - scale-up consistency 513-538 - single-use technologies 836-840 - substrate concentration 513-515 two-compartment reactors 521–538 FEM see finite-element models FFF see field-flow fractionation FIA see flow injection analysis fibril formation 173, 174 field-flow fractionation (FFF) 155, 156 filling applications 802, 810 film diffusion 417, 423-425 filtration techniques - plasmid DNA 22 - single-use technologies 800, 801, 812-815, 824-833 - see also ultrafiltration membranes finite-element models (FEM) 88 fixed costs 667-678 flasks 757 FlexFactoryTM 837-839 flow injection analysis (FIA) 360 flow-through chromatography see negative chromatography flow-unaffected resolution 335, 336 fluid dynamics 416-418 fluidized-bed adsorption 681 fluorescence-based biosensors 450 fluorescent product enhanced reverse transcriptase (FPERT) 598, 599 FMEA see failure mode and effects analysis formulation processes - amino acids and organic buffers 177 - chelating agents 178 - containers and closures 179 - freeze-drying 180-185 - freezing 179, 180 liquid formulations 175, 176, 181, 182 - PEGylated proteins 204

- pH effects 176 - plasmid DNA 7, 26-28 - redox potential 179 - salts 177, 178 - specific binding sites 178 - sugars and polyols 177, 180-185 - surfactants 178 - therapeutic proteins 165, 166, 175-185 four-column MCSGP principle 116-119 four-zone SMB systems 784 Fourier transform infrared (FTIR) spectroscopy 170, 194, 754 FPERT see fluorescent product enhanced reverse transcriptase fractionation chromatography 774, 775, 783, 784 freeze-drying 180-185 freezing 166, 169, 170, 179, 180 fructose-1,6-phosphate 622, 623 FTIR see Fourier transform infrared fungi – cell disruption processes 95 - fed-batch processes 522 - monoliths 339, 340, 360 - see also yeasts future-proofing 715

g

gamma-irradiation 601, 602, 798, 800, 801, 810.824 G-CSF see granulocyte colony-stimulating factor GAL see galactose-regulated genes galactose 632 galactose-regulated genes (GAL) 54, 55 GAM see glycoform activity modeling Gardasil 148, 149 gas chromatography-mass spectrometry (GC-MS) 754 GDH see glutamic acid dehydrogenase gel electrophoresis 475 gel filtration/size-exclusion chromatography 24 gene silencing 61 gene therapy vectors 588 genetic algorithms 723 genomic DNA - hydroxyapatite chromatography 307, 322 - monoliths 355-357, 361, 362 genomics 489, 491-493, 505-507 glass transition temperatures 182, 183 glucosamine 632 glucose oxidase (GOX) 360

> glucose-6-phosphate 623 glutamic acid dehydrogenase (GDH) 535, 536 glutamic acid synthase (GOGAT) 535, 536 glutamine 535, 536, 618-626 glutamine synthase (GS) 50, 535, 536 glutathione 248 glutathione peroxidase 248 glutathione S-transferase (GST) 248, 401, 465 glycerol cultivation media 17, 18 glycoform activity modeling (GAM) 573-580 glycolysis 618-626 glycoprofiling systems 571-573 glycoprotein-binding ligands 264 glycoproteins 208, 227, 228 glycosylation – A-MAb case study 552, 553, 556, 563, 579 - affinity chromatography 266 - biosensors 447, 448 - cost analysis 545-547 - domain ontology model 557, 577, 578 - efficiency of bioprocesses 626-632 - enhanced QbD 554-580 – glycoform activity modeling 573–580 - homogenous human-like glycoproteins 45-47 - Impact Maps 568-571, 575, 578 - informatics tools 554, 555, 557-561 - monoclonal antibodies 546, 552, 553 - Myozyme scale-up 548, 549 - Ontology Map 557-561, 564-568, 573-575 - optimization and comparability 545-583 - plant molecular farming 60 population model 555, 556, 561 - proteomics 476, 505 - QbD DS approach to comparability 546, 547, 551-580 - quality control 545-583 - scale-up processes 548-551 - SE Board 562-580 - traditional approach to comparability 547-551 - tuned glycoprofiling systems 571-573 - yeast protein production 54, 55 GMP see Good Manufacturing Practice GOGAT see glutamic acid synthase Good Manufacturing Practice (GMP) - integrated process design 714 membrane chromatography 401 - monoliths 338, 354, 355

- plastics 745, 746, 754, 764 - risk management 585, 601 - single-use technologies 803, 808, 810, 839, 849, 850 - virus-like particles 145, 151 Gorrod's view of inborn errors of metabolism 496, 505 GOX see glucose oxidase gradient experiments 416, 422, 423, 426 granulocyte colony-stimulating factor (G-CSF) 629, 631 graph theory and ontology (GTO) tools 554, 555 GS see glutamine synthase GST see glutathione S-transferase GTO see graph theory and ontology guanosine tetraphosphate (ppGpp) 516 gyrA mutations 15 h

HAC see hydroxyapatite chromatography HAR see human accelerated regions HCIC see hydrophobic charge induction chromatography HCP see host cell proteins HDPE see high-density polyethylene heat lysis 19, 20 HEK-293 see human embryonic kidney hemacytometry 632, 633, 636 hemagglutination inhibition (HI) test 469 Henderson-Hasselbalch equation 630, 631 Henry coefficients 414, 415, 419-422, 430, 431 heparin 247, 248, 383 hepatitis B vaccines 139-141, 145-147 hepatitis viruses 818, 820 HEPES buffer 297, 298 HI see hemagglutination inhibition HIC see hydrophobic interaction chromatography high-density polyethylene (HDPE) 747, 755, 756 high internal phase emulsions (HIPE) 333, 334, 337 high-performance affinity chromatography (HPAC) 226, 234 high-performance liquid chromatography (HPLC) - biosensors 464, 466 - efficiency of bioprocesses 641 - monoliths 339-346 - process design and management

692-694

- Quality by Design 412, 413, 416, 417 - therapeutic proteins 191, 192 high-pressure homogenization 81, 89-95, 102.103 high-throughput (HTP) bioprocesses 482, 650-652 high-throughput screening (HTS) 384 HIPE see high internal phase emulsions histidine 254, 255 histidine-tagged proteins 383 hok genes 11 hollow fiber bioreactors 748 homogenization 81, 89-95, 102, 103 homogenous diffusion model 782 homogenous human-like glycoproteins 45-47 hormones 227, 249 horseradish peroxidase (HRP) 256, 257 host cell proteins (HCP) - continuous chromatography 128, 129 - membrane chromatography 379, 398, 402, 403, 407 - process design and management 659 single-use technologies 798, 803 host strains 6, 11-16 HPAC see high-performance affinity chromatography HPLC see high-performance liquid chromatography HPV see human papillomavirus HRP see horseradish peroxidase HSA see human serum albumin HTP see high-throughput HTS see high-throughput screening human accelerated regions (HAR) 492, 493 human cell-based therapies 588, 600 human embryonic kidney (HEK-293) 52, 822-824, 833 human genome 492, 493 human insulin 695-697 human papillomavirus (HPV) 140, 147-152 Human Proteome Organization (HUPO) 479, 480 human serum albumin (HSA) 174, 178 HUPO see Human Proteome Organization hybrid technologies 805 hybridization chromatography 250 hydrodynamic conditions 526-529 hydrogen bonding 174 hydrophobic affinity chromatography 228, 253 hydrophobic charge induction chromatography (HCIC) 253, 255

hydrophobic interaction chromatography (HIC) - affinity chromatography 253, 254 - continuous chromatography 108 - continuous countercurrent chromatography 781, 787 - membrane chromatography 405, 406 - PEGylated proteins 212, 213, 217 - plasmid DNA 24 - process design and management 682, 685-689 - Quality by Design 414, 437 hydroxyapatite chromatography (HAC) 255, 256, 283-331 - advantages and disadvantages 303 - aggregation 284, 285, 317, 319, 320 - applications 313-323 - context 283-285 - displacement mode 309-313 - elution mode 305-309 - materials and interaction mechanisms 285-301 - NaCl/phosphate gradient protocol 306, 307 - patents 321 - phosphate gradient protocol 305, 306 - plasmid DNA protocol 307-309 - retention mechanisms 294-301 - set-up 301-312 - stationary phase properties 288 - structure-function relationships 289-294 - virus-like particles 150, 151 i ICH see International Conference on Harmonization IDA see iminodiacetic acid IGF see insulin-like growth factor IMAC see immobilized metal affinity

immobilized metal affinity chromatography iminodiacetic acid (IDA) 297, 383 immobilization chemistry 234, 235

immobilized metal affinity chromatography (IMAC) 228, 252, 253

membrane chromatography 383

- plasmid DNA 24

immunoaffinity adsorbents 239–242 immunogenicity

- plasmid DNA 7

- therapeutic proteins 165, 166

immunoglobulins *see* antibodies immunoprecipitation, proteomics 483 IMP *see* investigational medicinal products

Impact Maps 568-571, 575, 578

in silico process design 661, 662 in vitro adventitious agent tests 597 in vitro assembly/disassembly 141, 142, 152-154, 157, 158 in vitro binding assays 190, 191 in vivo adventitious agent tests 597 in vivo assembly 140-142, 147, 157, 158 inborn errors of metabolism 496, 505 inclusion bodies 99, 100 infectivity tests 597, 598 influenza viruses - membrane chromatography 396, 397 - monoliths 347, 348, 353 single-use technologies 845–848 - virus-like particles 145, 152 inheritance 490 inner particle diffusion 417, 423-425 inorganic monoliths 333 inorganic nanoparticles 28 insect cell lines 144, 145 insect glycoproteins 46, 55-57 insoluble protein inclusion bodies 99. 100 Installation Qualification (IQ) 809, 810, 814, 815, 834 insulin - continuous chromatography 107 process design and management 695-697 insulin-binding ligands 264 insulin-like growth factor (IGF)-1 99, 100 integrated process design 707-715 - Critical Quality Attributes 708-711 - knowledge spaces 710, 711, 713-715 - Process Control Strategies 710, 711, 713, 714 - Quality Target Product Profile 712, 713 - Target Product Profile 708, 709, 711 integrating plasmid (YIP) vectors 54, 55 interactomics 489, 501-503 interferometry 451-453, 455-457, 459-465, 467-470 interferons 205 International Conference on Harmonization (ICH) - integrated process design 707-715 - risk management 585, 602-605 - therapeutic proteins 188, 195 see also Quality by Design intrinsic factors 9-11 intrinsic fluorescence spectroscopy 187 investigational medicinal products (IMP) 602-606

ion-exchange chromatography - continuous countercurrent chromatography 769-773, 775, 776, 781 - hydroxyapatite chromatography 284, 285, 294, 295, 301, 311 - membrane chromatography 379, 400 - monoclonal antibodies 126, 131 - monoliths 342-346, 351, 355, 358 - PEGylated proteins 203, 204, 211, 212, 215-217 - plasmid DNA 23, 24 - polypeptide purification 121 - process design and management 681, 682, 685-689 - protein purification 108 - Quality by Design 414 - single-use technologies 834 - therapeutic proteins 191, 192 virus-like particles 152 ion-trap mechanism 630, 631 IQ see Installation Qualification isobaric labeling 485, 486 isocratic pulses 415, 416, 419, 420 isoelectric point 475 isoenzyme composition 339, 340 isotherm parameters 414, 416, 419, 426, 427 isothermal titration calorimetry (ITC) - biosensors 450, 468 - therapeutic proteins 166

j

jet machines 90

k

K-12 strains (*E. coli*) 4–6, 11, 48 Kaizen exercises 850, 851 kallikrein ligand 264 KC *see* Kozeny–Carman key performance indicators (KPI) 854 kinetic analysis 466–468 knowledge spaces 710, 711, 713–715 knowledge-based process understanding 646 Kozeny–Carman (KC) equation 336 KPI *see* key performance indicators

I

label-free biosensors 449–455, 464, 467 labeled biosensors 449, 450 lactate dehydrogenase (LDH) 634–638 lactate production 624, 626, 629 large decision spaces 720, 721, 731–736 LDH *see* lactate dehydrogenase

LDPE see low-density polyethylene leachables 174, 175, 753-755 least-square errors 416 lectins 227, 246, 247 legacy purification facilities 725-728 Leishmania tarentolae 64 lentiviruses 353 Lepidoptera spp. 144 ligand density 234 ligand immobilization 232-237 lignin peroxidase isoforms 339, 340, 363, 364 linear driving force model 782 lipoplexes 27 lipopolysaccharide (LPS) - affinity chromatography 270 - cell disruption processes 83, 98 - hydroxyapatite chromatography 302, 307 - membrane chromatography 399-401 - monoliths 358 - protein production technologies 49 – single-use technologies 798 liquid formulations 175, 176, 181, 182 liquid hold bags 794, 795 liquid-liquid extraction 682-684 live virus vaccines 588 low-density polyethylene (LDPE) 756 low-molecular weight contaminants 210-212 LPS see lipopolysaccharide Ludger tools 554, 555, 578 lyophilization - PEGylated proteins 204 - therapeutic proteins 166, 170, 175, 181, 182.184 lysate clarification 7, 21-23 lysozyme 296, 301, 380, 381

m

mAb see monoclonal antibodies MALDI-TOF see matrix-assisted laser desorption ionization time-of-flight mammalian cell lines 145, 146 mammalian glycoproteins 45, 50–53 manifolds 801, 823–833 mannitol 180–185 mannose glycosylation 46, 47 manufacturing costs 392 manufacturing executions systems (MES) 806, 809 market demands 745–747 marketing authorization 605, 606 mass loss index (MLI) 695, 696 mass spectrometry (MS) - proteomics 482-486, 499-501 - therapeutic proteins 192 mass transfer kinetics 413, 417-425, 782, 783 master cell banks (MCB) 588 matrix selection 232-237 matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) 483, 484, 500. 501 MCB see master cell banks MCSGP see multicolumn countercurrent solvent gradient purification Measurement Maps 571-573 mechanical cell disruption processes 81-98, 102, 103 medium dispensing 827-829 membrane chromatography 24, 25, 377-408 - aggregation 404-406 - applications 392-406 - bind-and-elute mode 377, 379, 381, 390, 391 - construction of absorbers 380-382 - DNA removal 398, 404 - economical modeling 391-393 - host cell proteins 379, 398, 402, 403, 407 - ligand types 382, 383 - lipopolysaccharide removal 399-401 - negative chromatography 379, 381, 389, 390 - plastics 761 - process design and management 681, 682 - resin-based chromatography comparisons 387-396, 398-407 - scaling-up with membrane adsorbers 384-387 - single-use technologies 798, 799, 804, 841, 842 - technical specifications of absorbers 377-387 - validation of membranes into purification process 392-395 - virus purification and vaccine manufacture 395.396 - virus removal 396-398 membrane technologies - biosensors 758, 759 - PEGylated proteins 203, 210-212, 214, 216 - single-use technologies 822-832 - virus-like particles 150 Mendel's principles of inheritance 490

MES see manufacturing executions systems metabolism 618-626 metabolomics 489, 505, 506 metal chelate adsorbers 383 metathesis polymerization 333 methacrylate monoliths 333, 334, 338-351, 355, 356, 361, 362 methionine sulfoximine (MSX) 50, 51 methotrexate (MTX) 50, 51 methylomics 489 Michaelis-Menten equation 362, 363 microfluidics-based biosensors 455, 457, 462.464 micromanipulation 93-95 microRNA 492 MIP see molecularly imprinted polymers mixed-integer nonlinear programming 723 mixed-mode affinity chromatography 229, 255.256 mixing operations 795-797, 814, 825-829 MLI see mass loss index MMV see mouse minute virus model error 425, 426 model parameter determination see experimental model parameter determination modular manufacturing environments 842-849 molecularly imprinted polymers (MIP) 229, 239–242, 250, 251 monitoring systems 808 monoclonal antibodies (mAb) - affinity chromatography 227, 230, 269-271 - biosensors 447 - capture and polish from supernatant 127-129, 131 - charge variant separation 125-127 - continuous chromatography 107, 111, 125 - 129 – continuous countercurrent chromatography 776, 786, 787 - glycosylation 546, 552, 553, 556, 578 - hydroxyapatite chromatography 303, 304, 313-321 - membrane chromatography 377-379, 388, 389, 396-399 - monoliths 341, 342, 350 - plastics 763, 764 process design and management 667-672, 683-687, 695, 725-728 - single-use technologies 819, 820, 836-840, 845-850 monolayer film structures 756

monoliths 333-375 - affinity chromatography 229, 251 - antibodies 340-342 - bioconversion of target molecules 360-362 - biosensors 360 - context 333 - downstream applications 340-348 - enzyme reactors 358-364 – enzyme-intrinsic properties 362–364 - hydroxyapatite chromatography 323 - negative chromatography 357, 358 - PEGylated proteins 342-344 - plasmid DNA 354-357 - preparative chromatography 348-358 - process analytical technology applications 338-348 - properties and characteristics 333-338 - protein purification 349-350 - proteome analysis 358-360 - upstream applications 339, 340 - viruses and VLPs 344-348, 351-353, 357, 358 monoproduct facilities 669, 671 monosulfone activation 206, 207 Monte-Carlo simulations - Quality by Design 409, 426-428, 432, 433, 440 - robustness and uncertainty 722, 732, 737 mouse minute virus (MMV) 586, 600, 601, 604, 605, 608 mouse myeloma cell lines 52 MS see mass spectrometry MSX see methionine sulfoximine MTX see methotrexate multicolumn continuous countercurrent chromatography 772-774, 779-781, 786, 787, 789 multicolumn countercurrent solvent gradient purification (MCSGP) 107, 109, 112-135 - applications 120-133 - batch chromatography 113, 114, 121-124, 126, 127, 130, 135 - bioseparations 112, 113 - decision tree 135, 136 – enabling features and economic impact 134, 135 - four-column MCSGP with separate CIP position 116-118 - four-column MCSGP with separate continuous feed position 118, 119 generic purification problem 114

- monoclonal antibodies 125-129

- polypeptide purification 120-125 - principles 113-120 - separations with more than three fractions 119.120 - six-column MCSGP principle 114 - size-exclusion chromatography 129-133 - three-column MCSGP principle 114, 115 multicomponent reactions 267, 268 multicriteria decision making 722, 723, 728 multifraction separations 119, 120 multiobjective optimization 725, 732 multiple conflicting outputs 720, 721, 728-730 multiple immobilization spots 457, 458 multiplex isobaric labeling 485, 486 multiproduct facilities 669-671 multivariate analysis 643-646, 720-723, 736-738 Mus dunni cell lines 598 Myozyme 548, 549

n

N-linked glycosylation - efficiency of bioprocesses 627 - protein production technologies 45-47, 54 - virus-like particles 146 N-terminal conjugation 208 natural selection 490 negative chromatography – membrane chromatography 379, 381, 389.390 - monoliths 357, 358 NEPAF see North East Proteome Analysis Facility net present value (NPV) 719, 725, 732-735 New Zealand 593-596 NMR see nuclear magnetic resonance nonenveloped viruses 600, 601, 605 nonpeptide mimetics 260 norleucine 518 North East Proteome Analysis Facility (NEPAF) 474, 478 norvaline 518 NPV see net present value NTU see number of transfer units nuclear magnetic resonance (NMR) 166, 167, 501 nucleic acids - affinity chromatography 227, 228, 249, 250 - efficiency of bioprocesses 632 - monoliths 337, 338

nucleotide synthesis 5 number of transfer units (NTU) 783, 785, 786 nutraceuticals 663 nutrient concentration 629 nutrient metabolism 618–626 nylon 747

0

O-linked glycosylation 45, 46, 627 Octet biosensors 453, 455-457, 459-465, 467-469 oligogalacturonides 361-363 oligonucleotides 338 oligosaccharides 626, 627 one gene/one enzyme concept 490, 496, 497 Ontology Map 557-561, 564-568, 573-575 open loop process control 648, 649 operating costs process design and management 667-678 - single-use technologies 819, 841, 842, 851, 856 Operational Qualification (OQ) 809, 810, 814, 815, 834 operator skills - process design and management 691 - proteomics 478 single-use technologies 815 optical biosensors 450-452 optimization 545-583 OQ see Operational Qualification orbitally shaken bioreactors 759 organic buffers 177 oxygen transfer processes 529-531

р

p10 gene promoters 56 package unit engineering 691-694 pallet tank systems 794, 795 PAM see protein A mimetic pandemic diseases 4 PAR see proven acceptable ranges paramagnetic matrices 234 Pareto frontiers 726, 727, 732-735 Parex process 774 particle size distribution - affinity chromatography 234 - cell disruption processes 100-103 - Quality by Design 414 PAT see process analytical technology PCA see principal component analysis PCR see polymerase chain reaction

nucleoside pathways 14, 15

PCS see photon correlation spectroscopy; Process Control Strategies PDVS see process development value streams PE see polyethylene PEGylated proteins 199-222 - amine conjugation 204-206 - chemistry of PEGylation 204-210 – click chemistry 209 - context 199, 200 - efficiency of PEG conjugation 200, 201 - free PEG removal 212, 213 - low-molecular weight contaminant removal 210-212 - monoliths 342-344 number of PEG adducts 202 - oxidized carbohydrate and N-terminal conjugation 208 positional isomerism 201, 202 - purification processes 203, 204, 210-217 - reversible PEGylation 209, 210 - separation from native protein forms 213-215 - separation of PEGylation species 215-217 - thiol conjugation 206, 207 transglutaminase-mediated enzymatic conjugation 208, 209 Penicillium chrysogenum 522, 696–699 peptide mimetics 258, 259 peptides - process design and management 685 - proteomics 484, 495 Peptostreptococcus magnus 243-245 PER.C6 cell line 52, 819, 831-839 performance prediction 783 Performance Qualification (PQ) 809, 814, 815 perfusion cultures 52, 53, 723 periplasmic inclusion bodies 99, 100 personalized medicine 506, 507 PFR see plug flow tube reactors pH effects – efficiency of bioprocesses 627 - therapeutic proteins 168, 169, 171, 172, 176 pH sensors 523-525 Phanerochaete chrysosporium 339, 340 phenyl isothiocyanate 497, 498 phosphoenolpyruvic acid-to-pyruvic acid ratio 515, 516 phosphofructokinase-1 624 phosphorylation 300, 503-505 photon correlation spectroscopy (PCS) 101

Pichia pastoris - protein production technologies 43, 44, 53-55,66 - virus-like particles 146 pillars of safety 590-602, 607, 608 PIMS level data management 644, 647, 651, 652 plant-based pharmaceuticals 663 plant cell lines 146 plant molecular farming (PMF) 46, 47, 59 - 62plant-wide automation structures 808, 809 plasma-derived products - continuous chromatography 107 - risk management 588, 600 plasmid DNA 3-41 - amplification systems 8, 9, 18, 19 - antigen selection 6, 7 - cell lysis 6, 19, 20 - chromatographic techniques 23-26 - context 3.4 - cultivation media and process conditions 16 - 19- endA and recA mutations 12, 15-17 - extraction processes 6, 19, 20 - formulation processes 7, 26-28 - gyrA mutations 15 - host strains 6, 11-16 - hydroxyapatite chromatography 297, 307-309, 322, 323 - inorganic nanoparticles 28 - intrinsic factors 9-11 - lipoplexes 27 - lysate clarification 7, 21-23 - monoliths 354-357 - nucleoside pathways 14, 15 - polyplexes 27, 28 production requirements 4–6 - protein production technologies 49, 50, 54, 55 - purification processes 7, 20-26, 354-357 - relA mutations 12-14, 16 - strains for production processes 15, 16 - structure of production process 6, 7 - vector constructs 6, 8-11 Plasmodium falciparum 146 plastic modulus 85, 86 plastics 745-767 - case study 761-763 - cultivation devices 757-763 - driving forces 745-747 - environmental factors 753-755 - future prospects 763-765 - leachables and extractables 753-755

- material to function 747-753 - purification devices 760, 761 - single-use technologies 821, 824 - storage devices 755-757 plastid transformation 60 plate theory 232 platform processes 605, 606, 662, 776, 777, 805.806 plug flow tube reactors (PFR) 521-538 PMF see plant molecular farming Poisson ratio 86 polh gene promoters 56 polh promoters 144 polyacrylamide-coated ceramics 333 polyacrylamide gel monoliths 333 polyamides 752, 753 polycarbonate 752 polyclonal antibodies 390, 391 poly(ethylene glycol) see PEGylated proteins polyethylene (PE) 747-749, 755, 756 polvethylene terephthalate 756 polyHIPE monoliths 333, 334, 337 polyhistidine-tagged proteins 383 polymerase chain reaction (PCR) - proteomics 491 - risk management 592, 593, 598, 599 polymethacrylate monoliths 333 polynucleotides 302-312, 318, 319, 322, 323 polyols 177 polyomaviruses 152, 153 polypeptides - continuous chromatography 120-125 - hydroxyapatite chromatography 296, 300 polyplexes DNA 27, 28 polypropylene (PP) 748, 749, 755, 756 polysaccharides 227, 228 polystyrene (PS) 747, 748, 750 polysulfones 748, 750 polytetrafluoroethylene (PTFE) 749 polyvinyl chloride (PVC) 751, 752, 756 polyvinylidene 749 population balance theory 103 population model 555, 556, 561 porcine circovirus (PCV) 585, 586, 592 pore diffusion 417, 423-425, 431 pore size affinity chromatography 233, 234 - hydroxyapatite chromatography 287 - monoliths 337, 354 - single-use technologies 798, 799 porosity - membrane chromatography 380, 381, 387, 388

- monoliths 336 - Quality by Design 430, 431 porous-media chromatography 151 porous monolithic supports 25, 26 portfolio management 720, 731-736 positional isomerism control 201, 202 post-transcriptional modifications 503-505 PP see polypropylene ppGpp see guanosine tetraphosphate PQ see Performance Qualification precipitation processes - monoliths 342 - plasmid DNA 21, 22 - process design and management 684, 685 - protein production technologies 59 - therapeutic proteins 173, 174 predictability 647, 648 prepacked columns 780, 781 preservatives 813, 814 primary protein structure 493-495 principal component analysis (PCA) 723, 737 probes 758, 759 Process Analytical Technology (PAT) - continuous countercurrent chromatography 778 - efficiency of bioprocesses 613–616, 626, 638-653 - monoliths 338-348 - process design and management 690 - risk management 585 - single-use technologies 808, 849-851 process condition variability 431-439 Process Control Strategies (PCS) 711, 713, 714 process design and management 659-705 - antibiotics 696-699 - Anything And Chromatography concept 679-685 - batch to continuous manufacturing 672-679 - context 659-662 - continuous countercurrent chromatography 779-786 - data visualization 721-723 - decision-support tools 719-723, 739 - downstream of downstream processing 694, 695 - downstream processing 659-661, 663-665, 667-689, 692 - facility design 719, 725-737 - human insulin 695-697

- integrated process design 707-715

- large decision spaces 720, 721, 731-736 - management strategies 717-741 - monoclonal antibodies 667-672, 683-687, 695 - multiple conflicting outputs 720, 721, 55 - 57728-730 multivariate analysis and stochastic simulations 720-723, 736-738 package unit engineering and standardization 691-694 process concepts in biomanufacturing 663-665 - process integration 685-689, 699 production technologies 662–679 - Quality by Design 661, 689-691, 57-59 699 - robustness 719-721, 723-728 66 - single-use technologies 793, 804-806, 840 - synergies 662, 663 171 - total process analysis 664, 666-672 - uncertainty 717-730 - upstream processing 659-661, 663, 664, 671, 672, 679 process development value streams (PDVS) 849-854 process integration 685-689, 699 process modeling 411-414 process understanding and control 639-649 process validation 811-815 product bacteria challenge tests 812-814 product complexity 587-590 product life cycle 708, 709, 714 product transfer 797, 798 proof-of-concept 647, 648, 852 proteins proof-of-principle 686, 781 protease inhibitors 62 protein A chromatography - affinity chromatography 242-245, 269-271 – continuous countercurrent chromatography 786, 787 - hydroxyapatite chromatography 283-285, 319.320 membrane chromatography 378 - single-use technologies 798, 834, 840, 841 protein A mimetic (PAM) 259, 262-264 Protein Data Bank 501 protein G chromatography 242-245 507 protein G monoliths 340, 341 protein L chromatography 243–246 protein L mimetic 264, 268

protein production technologies 43-77 - bacteria as protein factories 43, 44, 47-50, 63, 65, 66 - baculovirus-insect cell technology 43, - cell-free protein production 44, 62-65 - context 43, 44 - future prospects 65, 66 - glycoengineering for homogenous human-like glycoproteins 45-47 - mammalian cell technology 45, 50-53 - plant molecular farming 46, 47, 59-62 - transcription/translation efficiency 61, 62 - transgenic animal technologies 43, 44, - yeast protein production 43-46, 53-55, protein stability 165-175 - air-liquid and solid-liquid interfaces 170, - chaotropes, solvents and pH 168, 169 - chemical stability 171-173 - drying 170 - freezing 169, 170 - leachables 174, 175 - physical stability 165, 167-171, 185, 186 - precipitation, aggregation and fibril formation 173, 174, 180, 182, 183, 186, 192, 193 - shear 169 - stability testing 166, 188-194 - structural stability 167, 168 - thermal stability 168, 186, 187 protein-carbonate interactions 266 protein-protein interactions 502, 503 - affinity chromatography 227, 228, 230, 235-237, 242-246 - biosensors 464, 465 - continuous chromatography 107-137 - hydroxyapatite chromatography 293-300, 302-315 - monoliths 339, 349, 350 - risk management 587 - structure 493-495 - see also proteomics; therapeutic proteins proteomics 473-487 applications 475–477, 506–508 - availability problem 474 - biological advances 489, 490, 495-498 - biomarkers of human diseases 503-505, - brain diseases 499, 508 - case studies 481-486

- complex diseases and personalized medicine 506, 507
- context 473
- definition and characteristics 474, 475
- differentiation of multicellular organisms 501, 502
- diseasome concept 503, 504
- drug development 507
- drug discovery 506, 507
- expertise and training 478
- genomics 489, 491-493, 505-507
- historical development 489–492, 495–501
- industrialization 480, 481
- interactomics 489, 501-503
- isobaric labeling 485, 486
- mass spectrometry 482–486, 499–501
- matrix-assisted laser desorption ionization
 483, 484, 500, 501
- Mendel's principles of inheritance 490
- metabolomics 489, 505, 506
- monoliths 358-360
- myths and misconceptions 477-480
- one gene/one enzyme concept 490, 496, 497
- protein identification and characterization 475, 476
- protein interactions 476
- protein modifications 476
- protein separation, sequencing and throughput technologies 492
- protein structure 493-495
- quality control 480, 481
- quantitative approaches 477, 484-486
- reproducibility 479, 480
- robustness and reliability 481
- sciences of omics 489, 490
- set-up costs 477, 478
- stable isotope labeling 484, 485
- technological advances 491, 492, 497–501
- throughput and time-consumption 478, 482
- two-dimensional PAGE 477, 479, 481, 482, 498, 499
- Watson–Crick structure of DNA 490, 491
- X-ray crystallography and NMR 501
- ProteOn biosensors 457, 461, 464
- proven acceptable ranges (PAR) 646
- pseudoviruses (PSV) 139
- PSV see pseudoviruses
- PTFE see polytetrafluoroethylene
- pUC plasmids 8
- purification performance index 666
- purification pyramid 238

purity–yield plots 438, 439, 686 PVC *see* polyvinyl chloride pyruvate 621, 623–625 pyruvate kinase 623, 624 pyruvic acid 515, 516, 520, 533–535

9

- QA see quaternary amine
- QbD see Quality by Design
- QMS see Quality Management System
- QRM see quality risk management
- QSPR see quantitative structure-property relationships
- QTPP see Quality Target Product Profile qualification processes 809–811, 834
- Quality by Design (QbD) 409–443
- A-MAb case study 552, 553, 556, 564, 579
- context 409
- continuous countercurrent
- chromatography 778
- domain ontology model 557, 577, 578
- efficiency of bioprocesses 613–616, 638–653
- enhancement 554-580
- experimental model parameter determination 414–431, 437–439
- fluid dynamics 416-418
- fundamental principles 410, 411
- glycoform activity modeling 573-580
- glycosylation 546, 547, 551-580
- Impact Maps 568-571, 575, 578
- informatics tools 554, 555, 557-561
- integrated process design 707-715
- isocratic pulses 415, 416, 419, 420
- isotherm parameters 414, 416, 419, 426, 427
- mass transfer kinetics 417-425
- method overview 410
- model error 425, 426
- modeling principles 413, 414
- Ontology Map 557–561, 564–568, 573–575
- population model 555, 556, 561
- process challenges 412
- process design and management 661, 689–691, 699
- process modeling 411-414
- robustness analysis 409, 424-439
- SE Board 562–580
- single-use technologies 849-851
- tuned glycoprofiling systems 571-573
- variation of process conditions
 431–439

quality control

- efficiency of bioprocesses 613–656
- fed-batch processes 513-538
- glycosylation throughout the drug life cycle 545-583
- optimization and comparability 545-583
- proteomics 480, 481
- risk management 585-612 scale-up consistency 513–543
- virus safety 585–612
- Quality Management System (QMS) 551 quality risk management (QRM) 585-590 Quality Target Product Profile (QTPP) 547, 551-553, 556, 558-561, 573-578, 711, 712 quantitative proteomics 477, 484-486 quantitative structure-property relationships (OSPR) 299, 312 quarantine 595, 596 quaternary amine (QA) monoliths 340, 341, 343-345, 352, 353 quaternary ammonium (Q) membranes 389-394, 396-398, 402-404 quaternary protein structure 493-495
- quiescent normal cells 622, 623

r

rabies virus 819, 820 Raman spectroscopy 194 rate theory 232 recA mutations 12, 15, 17 recombinant proteins - affinity chromatography 246, 248, 249, 265 - glycosylation 550 - hydroxyapatite chromatography 293, 294, 297.298 - process design and management 666 - protein production technologies 43, 44, 51, 52, 58-62 - proteomics 485 risk management 587 - virus-like particles 139-141, 145 recycling and recovery processes 694, 695 red biotechnology 659, 663 red cell aplasia 165 redox potential 179 refractive index 451, 453, 455 regulatory issues - efficiency of bioprocesses 613-617 process design and management 659, 660, 717 - quality control 546-549

- risk management 585, 595, 596, 602–606
- therapeutic proteins 188

regulatory targets 621-624 relA mutations 12-14, 16 release of biopharmaceuticals see cell disruption processes reliability 481 reproducibility 479-480, 647, 648 residence time distributions (RTD) 97 residual risk 600, 601 resonant waveguide grating (RWG) 452-455, 458-464 retention mechanisms 294-301 retroviruses 597-599 reverse transcriptase assays 598, 599 reversed-phase chromatography efficiency of bioprocesses 641 - PEGylated proteins 215, 216 - polypeptide purification 121 - protein purification 108, 109 - therapeutic proteins 191, 192 reversible PEGylation 209, 210 Rhizopus oryzae 361 ribonucleic acid see RNA ribosomal RNA 492 risk management 585-612 - biopharmaceutical product classes 587, 588 - clearance and residual risk control 600. 601 - contamination events 585, 586, 589 - CPMP guidance 602-606 - epidemiology 592-596 - generic data 603 - integrated process design 709, 711, 713, 714 - media and API supplier control 601, 602 - pillars of safety 590-602, 607, 608 - plastics 754 - platform purification processes 605, 606 - product complexity 587-590 - quality risk management 585-590 - risk minimization strategy development 607.608 - sourcing and baseline risk 590-596, 599, 600 - testing and baseline risk reduction 596-600 - uncertainty 722 - validation requirements 604-606 - virus safety 585-612 - well-characterized cell lines 603, 604 RNA aptamers 227, 228, 249, 250 RNA I/RNA II complex 8, 9

- RNA removal 361
- RNA sequencing 492

robustness analysis – model error 425, 426 – model parameter determination error 426–431, 437–439 – proteomics 481 – Quality by Design 409, 424–439 – uncertainty 719–721, 723–728 – variation of process conditions 431–439 rom genes 8, 9 rotavirus vaccines 586 RTD see residence time distributions RWG see resonant waveguide grating

S

Saccharomyces cerevisiae - affinity chromatography 242, 265 - cell disruption processes 83-85, 92-94, 102.103 - fed-batch processes 521, 522 - monoliths 360 - process design and management 666 - protein production technologies 43, 44, 53 - 55- virus-like particles 146, 148 safety-efficacy space (SE Board) 562-580 safety issues 793, 800, 848 - see also risk management safety tripod 590-602, 607, 608 salts 177, 178 sample handling 455-458 Sankey diagrams 695, 697, 698 SAR see structure-activity relationship SAT see Site Acceptance Test SCADA see supervisory control and data acquisition scale-down reactors 520-523 scale-up processes - efficiency of bioprocesses 638, 639 - glycosylation 548-551 - optimization and comparability 548-551 - quality control 513-543 - single-use technologies 824-829 scatter plots 433-435 screening kits 482, 483 SDS-PAGE see sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDVB see styrene-divinylbenzene SE Board 562-580 SEC see size-exclusion chromatography secondary protein structure 493-495 secretory proteins 627, 628 selective displacement chromatography 313 SELEX see systematic evolution of ligands by exponential enrichment

semi-continuous processes 63, 64 sensitivity analysis - model parameters 430 - process conditions 436, 437 - robustness and uncertainty 723, 730 Sepharose 483 sequence-directed recognition peptides 258, 259 Serratia marcescens 520 set-up costs 477, 478 shear 169 sialvlation 629-632 silica-based affinity chromatography 234 silica monoliths 333, 334 silica xerogel monoliths 333 simulated moving bed (SMB) process 109-113, 770-775, 778-781, 784, 786-789 single nucleotide polymorphisms (SNP) 492, 493 single-use technologies 793-816 - assessment 854-856 - automation systems 806-809 - continuous countercurrent chromatography 777, 778, 780, 786, 789 - Crucell NV case study 817-858 - current applications 793 - data acquisition 808 - downstream opportunities 804, 837, 842 - equipment qualification 809-811 - facility design 843-849 - filling applications 802, 810 - filtration applications 800, 801, 812-815, 821-833 - future applications 802-806 - future prospects 856, 857 - industrialization and simplification 829-835 - liquid hold bags 794, 795 - mixing operations 795-797, 814 - modular manufacturing environments 842-849 - monitoring and control 808 - operator training 815 - plant-wide automation structures 806, 809 - plastics 745-747 - process development value stream 849-854 - process engineering 804-806 - process validation 811-815 - product and component transfer 797, 798 - purification applications 798-800 - robustness and uncertainty 728-730

- scale-up, capsules and coupling 824-829

880 Index

- small-scale plastic cell culture units 821, 822 - sterile connections 801, 806, 822-832 - three phase evolution 821-836 - upstream opportunities 803, 837, 840 SIP see sterilization-in-place Site Acceptance Test (SAT) 809, 834 site-specific PEGylation 202, 209 six-column MCSGP principle 114 size-exclusion chromatography (SEC) - continuous chromatography 129-133 – continuous countercurrent chromatography 782, 784, 788, 789 - hydroxyapatite chromatography 284, 285 - PEGylated proteins 203, 210-217 - therapeutic proteins 192, 193 virus-like particles 152, 154 SMA see steric mass action small- and medium-sized enterprises (SME) 662, 692, 731, 732 small RNA 492 small-scale stirred disposable bioreactors 759 SMB see simulated moving bed SME see small- and medium-sized enterprises SNARE interactions 468 SNP see single nucleotide polymorphisms SOD see superoxide dismutases sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 193, 194, 347, 348 soft-gel-based matrices 233, 234 sok genes 11 solid-liquid interfaces 170, 171 solvent effects 168, 169 SOP see Standard Operating Procedures Sorbex process 773 sourcing animal-derived materials 590-596, 599,600 spacer arms 234-236 spider plots 730 spiking studies 394, 397 spin-filter perfusion culture 723, 725 Spodoptera spp. 56, 144, 145 sporulation cascade 517 SPR see surface plasmon resonance stability testing – accelerated 189 - analytical techniques 189-194 - cell-based bioassays and in vitro binding assays 190, 191 regulatory issues 188 therapeutic proteins 166, 188–194 stable isotope labeling 484, 485

stainless steel 728-730, 794, 801 Standard Operating Procedures (SOP) - proteomics 479 - single-use technologies 805, 810, 815, 852-854 standardization 691-694 Staphylococcus aureus - affinity chromatography 242-245 - membrane chromatography 377-379 - monoliths 352, 353 - protein production technologies 49 static batch shaking experiments 415, 420 steam sterilization see autoclaving stem cells 588 steric effects 207, 235 steric mass action (SMA) model 414 sterile connections 801, 806, 822-832 sterile transfer systems 797, 798 sterilization 798, 800, 801, 810, 821, 831, 834.838 sterilization-in-place (SIP) - affinity chromatography 251, 259, 263 - single-use technologies 820, 821, 839 sterilizing-grade filters 800, 801, 812-815 stirred tank reactors (STR) 513, 520-538 stochastic simulations 720-722, 736-738 Stokes equation 100 storage plastics 755–757 - therapeutic proteins 166, 169, 170, 180 STR see stirred tank reactors streptavidin 248, 249, 383 Streptococcus spp. 140, 141, 242-245 stress-strain tests 85, 86 structural stability 167, 168 structure-activity relationship (SAR) model 547, 560, 561, 564, 565 structure-function relationships 289-294 Student's deviation 428 styrene-divinylbenzene (SDVB) monoliths 347, 348 subcellular targeting 62 sublimation processes 183 succinic acid 535 succinimidyl carbonate activation 205 succinimidyl propionate activation 214 succinimidyl succinate activation 205 sugars 177, 180-185 superhelicity 5, 16, 17, 355, 356 superoxide dismutases (SOD) 209 supervisory control and data acquisition (SCADA) 806, 809 surface plasmon resonance (SPR) - biosensors 452-458, 460-465, 467-470 - therapeutic proteins 166

surfactants 178 synthetic and designed ligands - affinity chromatography 228, 229, 240, 251-269 - benzhydroxamic acid 256, 257 - biomimetic ligands 251, 258-269 - boronate affinity chromatography 228, 256 - de novo affinity ligands 260-269 - dye-based ligands 228, 257, 258 - histidine 254, 255 - hydrophobic ligands 228, 253 - immobilized metals 228, 252, 253 mixed-mode affinity chromatography 229, 255, 256 - thiophilic ligands 228, 253, 254 systematic evolution of ligands by exponential enrichment (SELEX) 227, 228, 250 t T7 RNA polymerase 48, 49 TAC see thiophilic affinity chromatography tangential flow applications 842 Target Product Profiles (TPP) 134, 135, 708, 709, 711 TCA see tricarboxylic acid technology transfer 737, 765 TEM see transmission electron microscopy temperature-sensitive mutations 9 tertiary protein structure 493-495 testing animal-derived materials 596-600 TGase see transglutaminase therapeutic proteins 165-198 - accelerated and long-term stability testing 188-194 - air-liquid and solid-liquid interfaces 170, 171 - amino acids and organic buffers 177 - analysis and characterization 166

- chaotropes, solvents and pH 168, 169, 171, 172, 176
- chelating agents 178
- chemical stability 171–173
- containers and closures 179
- context 165-167
- drying 170
- formulation processes 165, 166, 175-185
- freeze-drying 180–185
- freezing 166, 169, 170, 179, 180
- leachables 174, 175
- liquid formulations 175, 176, 179, 180
- physical stability 165, 167-171, 185, 186
- precipitation, aggregation and fibril formation 173, 174, 180, 183, 184, 186, 192, 193

- protein stability 165-175, 185, 186 - redox potential 179 - salts 177, 178 - screening methods 185-187 - shear 169 - specific binding sites 178 - structural stability 167, 168 - sugars and polyols 177, 180-185 - surfactants 178 - thermal stability 168, 186, 187 thermal stability 168, 186, 187 thermo-responsive displacers 311, 312 Thermus thermophilus 361 thiol conjugation 206, 207 thiophilic affinity chromatography (TAC) 228, 253, 254 three-column MCSGP principle 114, 115 tissue engineering 588 tissue plasminogen activator (tPA) 50 tomato mosaic virus (ToMV) 351, 352 total process analysis 664, 666-672 tPA see tissue plasminogen activator TPP see Target Product Profiles track-and-trace systems 809 training - process design and management 691 - proteomics 478 single-use technologies 815 transcription efficiency 61 transfection efficiency 5 transfection-grade DNA 5, 6 transfer RNA (tRNA) - fed-batch processes 518 - plasmid DNA 9, 10 - proteomics 492 transfer systems 797, 798, 822, 823 transferrin 341 transgenic products - protein production technologies 43, 44, 57-59 - risk management 588 transglutaminase-mediated enzymatic conjugation 208, 209 translation efficiency 61, 62 transmission electron microscopy (TEM) 154 triangle theory 784 triazine-based affinity ligands 228, 262-266 tricarboxylic acid (TCA) cycle - efficiency of bioprocesses 619-621, 625 - scale-up 515-518, 535, 536 Trichoplusia ni 56, 144, 145 tRNA see transfer RNA trypsin 359, 360 trypsinogen 390, 391

- 882 Index
 - tubes 757 tumor cells 622–624 tuned glycoprofiling systems 571–573 two-compartment reactors 521–538 two-dimensional polyacrylamide gel electrophoresis (PAGE) 477, 479, 481, 482, 498, 499 two-film model 782

и

UDP-GlcNAc pools 629-632 Ugi ligands 228, 267-269 ultra-low-density polyethylene (ULDPE) 756 ultrafiltration membranes - PEGylated proteins 203, 210-212, 216 - single-use technologies 798, 800, 804 ultraviolet (UV) fluorescence spectrometry 194 ultraviolet (UV) inactivation 799, 800 uncertainty 717-730 - multiple conflicting outputs 720, 721, 728-730 - risk management 722 - robustness 719-721, 723-728 untranslated regions (UTR) 61 uptake curves 416, 421 urine-derived products 588 UTR see untranslated regions UV see ultraviolet

V

vaccines - biosensors 468, 469 continuous countercurrent chromatography 788, 789 - design and efficacy 468, 469 - membrane chromatography 395, 396 - plasmid DNA 3-41 - risk management 586, 588 - single-use technologies 819, 821, 845-849 - virus-like particles (VLP) 139-141, 145-148 validation - integrated process design 707 - membrane chromatography 393-395 - risk management 604-606 - single-use technologies 793, 811-815 value streams 849-854 valve machines 89, 90 van Deemter analysis 417, 434 variable costs 667-672, 694 vector constructs 6, 8–11

vertical parallel coordinate plots 737, 738 vesivirus 2117 585, 586, 608 VHH ligands 241, 242 viability index 635-638 vials 755 viremia levels 592, 608 virus-like particles (VLP) 139-163 - aggregation 149, 150, 153, 154 - analysis and characterization 154-157 - context 139, 140 - continuous countercurrent chromatography 788, 789 - downstream processing 147-154 - Gardasil downstream processing 148, 149 - in vivo and cell-free assembly 140-142, 147, 157, 158 - intracellular expression and assembly 143-146 - monoliths 344 - protein production technologies 55-57 - purification of cell-assembled VLPs 150-152 - purification for in vitro assembly 152-154 - upstream processing 143-147 viruses - contamination events 585, 586, 589 - hydroxyapatite chromatography 302 - membrane chromatography 383, 394-398 - monoliths 344-348, 351-353, 357, 358 - plasmid DNA 3, 4 - risk management 585-612 - single-use technologies 798-800, 804, 818, 819, 845-849 viscosity radius 213 vitamins 227, 249 VLP see virus-like particles volumetric yields 5, 6 von Mises stress/strain 86, 103 w

wall-strength model 92, 93
water for injection (WFI)
process design and management 695, 696
single-use technologies 794, 800, 824–829, 845
Watson–Crick structure of DNA 490, 491
wave-mixed bioreactors 759, 760, 795
Western blotting 193, 194
wetting agents 814
WFI see water for injection

wheat germ agglutinin (WGA) 246, 247 white biotechnology 663

X

X-ray crystallography 167, 501 Xcellerex bioreactors 833, 834, 837–841, 848–850, 854–856 xenogeneic cell-based therapies 588 xenotransplantation products 588

Y

YCP *see* centromeric plasmid yeasts

- affinity chromatography 242, 265
- cell disruption processes 83–85, 87–95, 102, 103

- fed-batch processes 517, 518, 520, 521
- monoliths 360
- process design and management 666
- protein production technologies 43–46, 53–55, 66

virus-like particles 139, 140, 146, 148
YEP see episomal plasmid
yield/productivity performance 133
yield/purity trade-offs 126, 127
yield stress 85, 86
YIP see integrating plasmid
Young's modulus 85, 86, 88

z

zinc-modified hydroxyapatites 293, 294 zoonotic viruses 591, 593–596